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ABSTRACT 
Objective: The drug will provide a therapeutic effect when dissolved so that it is easily absorbed. The process of dissolving drugs is called 
dissolution. Additional substances contained in pharmaceutical preparations, one of which serves to accelerate the solubility of active substances. 
The aim of this study was to obtain a comparative composition of Ludipress® and lactose additives suitable for producing ambroxol HCl tablets that 
met the ambroxol acceleration ambroxol in the body.  
Methods: Ambroxol HCl tablets were made by direct pressing method. For research purposes, 4 formulas with variations of Ludipress® and Lactose were 
designed. The tablet was then evaluated, which includes uniformity in weight, diameter, thickness, hardness, friability, disintegration time, and dissolution. 
Data obtained in the analysis using the perfect random block design method (DBAS) with α = 0.05 where blocks and groups were used.  
Results: From the results of the Mass Printing Evaluation of Tablets, it was found that the four formulas that were designed met the resting angle, 
flow rate, real density, compressed density, and compressibility met existing requirements. The results of evaluation tablets, which included 
uniformity of weight, uniformity of size, hardness, friability, disintegration time, and dissolution test, were found that only F1 formula did not meet 
uniformity requirements. All four formulas meet the Indonesian pharmacopeia requirements for time of violence, fragility and disintegration. The 
dissolution test results showed that in the 45-minute test each percent dissolved concentration of the active substance for F1, F2, F3, and F4 was 
58.77974, 66.91104, 80.09946, and 64.02293 suggesting only the F3 formula fulfilled the dissolution requirements according to European 
Pharmacopoeia which stated that the concentration of dissolved active tablets should not be less than 75% during the 45-minute test.  
Conclusion: The formula that met the solubility requirements consisted of an additional 69% Ludipress® and 10% lactose with a solubility value of 
80.09%.  
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INTRODUCTION 
Dissolution test is one of the tests most often used to characterize drugs 
and control the quality of dosage forms. Investigation through 
dissolution carried out on powders enables optimization of formulation 
factors [1, 2]. Optimal dissolution can be obtained if the tablet can be 
crushed into particles quickly. It is generally known several years ago 
that before absorption occurs, a solid drug must undergo disintegration 
into small particles and release the active substance [3, 4]. 
Actually, there was some research regarding the ambroxol HCl 
tablet. Sharma et. al [5], for example, wrote simultaneous estimation 
of ambroxol hydrochloride and cetirizine hydrochloride in 
pharmaceutical tablets using simultaneous equation 
spectrophotometric. Basak et. al [6] mentioned formulation and 
release behavior of sustained-release ambroxol hydrochloride HPMC 
matrix tablet. A study on the effect of 20 mg ambroxol hydrochloride 
on acute cough was articled by Hull University Teaching Hospitals 
NHS Trust [7]. In vitro characterization and release study of 
ambroxol hydrochloride matrix tablets prepared by direct 
compression was reported by Abd-Elbary et. al [8, 9]. Rangnath et. al 
[10] studied Development and validation for UV Spectrometric 
estimation of ambroxol hydrochloride in bulk and tablet dosage 
form using the area under curve method. Kinetic studies of ambroxol 
were studied by Akhter et. al [11] and Hang et. al [12]. Method for 
simultaneous estimation of levofloxacin hemihydrate and ambroxol 
hydrochloride in bulk and its pharmaceutical dosage form was 
reported by Sumithra et. al [13]. Potawale et. al [14], however, used 
Liquid chromatography tandem-Mass spectromethry to develop a 
method for simultaneous analysis of paracetamol, guafenesin, 
phenylephrine hydrochloride, chlorpheniramine maleate, and 
ambroxol hydrochloride in bulk and tablet dosge form. Our current 
research is different from existing research studies. 
Ludipress® is an additive or excipient consisting of 93% lactose, 
3.5% Kollidon® 30, and Kollidon CL. Lactose functions as a carrier 
and filler, Kollidon®30 as a binding agent, and Kollidon CL as a 
disintegrator. So that Ludipress® is a granule with a good flow rate, 
is not too hygroscopic, and has a strong tie. This makes the process 
of mixing with active substances become more homogeneous and 
can be pressed directly so as to produce high-quality tablets. Tablet 
formulations using Ludipress® only require active substances, 
Ludipress®, and lubricants, and then mixed and can be directly 
pressed [15, 16]. 
Ambroxol Hydrochloride is a compound used as a cough medicine 
that is as a mucolytic. Mucolytic is a drug that can thin the airway 
secretions by breaking the threads of mucoproteins and 
mucopolysaccharides from mucus. Mucus removal becomes easy, so 
it relieves breathing. Ambroxol is completely absorbed after oral 
administration. It breaks up phlegm, used in the treatment of 
respiratory diseases associated with viscid or excessive mucus. 
Recently, a hypothesis suggested that it may have a potential role in 
the treatment of Paget's disease of bone, Parkinsonism, and other 
common diseases of aging-associated diseases involving dysfunction 
of autophagy. The dose of Ambroxol Hydrochloride is between 30 
mg to 120 mg per day for adults [17-19]. In this study, ambroxol, HCl 
tablets were made by direct pressing using a variation of 
Ludipress® and lactose additives in an effort to accelerate the 
solubility of active substances. 
MATERIALS AND METHODS 
Tools 
Dissolution type 2 (Sotax), UV-VIS spectrophotometer (Analytic 
Jena), tapped density test equipment(Varian 50-1300), hardness 
tester (Erweka), tablet friability test equipment (Varian 453200), 
analytical balance (Mettler Toledo), single punch tablet machines 
(Korsch), crushed time test equipment (Erweka ZT3), sieves, 
thermometers, calipers, and glassware commonly used in 
laboratories. 
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Materials 
The materials used in this study were ambroxol HCl (Dong Wha), 
Ludipress® (BASF), Lactose mesh 80 (DMV Fonterra). 
Methods 
Raw Material Preparation: Preparation of active substances based 
on Indonesian Pharmacopoeia literature [20, 21]. Preparation of 
additional substances based on the Handbook of Pharmaceutical 
Excipient literature [22, 23]. 
Tablet formulation 
In this study, four ambroxol, HCl tablet formulations were made with 
variations of additives Ludipress® and lactose. The ambroxol HCl 
tablet formulation can be seen in table 1. 
 
Table 1: Designed formula tablet ambroxol HCl 
Formula F1 F2 F3 F4 
Ambroxol HCl 30 mg 30 mg 30 mg 30 mg 
Mg. Stearate 1 mg 1 mg 1 mg 1 mg 
PVP K-30 15 mg 15 mg 15 mg 15 mg 
Ludipress® 79% 74% 69% 64% 
Lactose - 5% 10% 15% 
 
Tablet making 
Tablets were made using the direct pressing method. The ingredients 
were sifted and weighed as needed. Ambroxol HCl was added with 
additional substances Ludipress®, lactose, and PVP K-30 according to 
the designed formula and mixed for about 10 min. After mixing, 
magnesium stearate was added and mixed again for about 30 sec. 
The printed mass of tablets obtained was then evaluated against 
Flow Rate and Rest Angle, Real density, compressed density, and 
compressibility. The data obtained later would be referred to 
Relationships between flow rate and powder flow properties, resting 
angles and flow traits, and between the nature of powder flow with 
compressibility given by Aulthon [24]. Designed tablets were 
evaluated against Size of uniformity, Uniformity of weights, Tablet 
hardness, Toughness tablet, and Dissolution test.  
Print mass evaluation 
a. Flow Rate and Resting Angle: The mass of the press was placed 
in the flow rate test funnel whose bottom was closed. The mass of 
the press coming out of the tool was calculated its flow rate by 
calculating the time required by a number of powders to descend 
through the test tube funnel using a stopwatch. The calculation 
started when the bottom lid of the funnel was opened until all the 
mass of the press flows out of the tool.  
Print mass deposits could be used to calculate the angle of rest. The 
average diameter of the pile and the height of the top of the pile 
were measured. The relationship between the angle of rest and the 
nature of the powder flow would be referred to Aulthon [24].  
b. Real density, compressed density, and compressibility: Actual 
density was determined by placing a number of print masses into a 
measuring cup and then measuring its volume and calculating its 
density by the following formula [24]. 
 
Pressure could be seen from the value of Carr's compressibility 
index, which was very dependent on the real density and 
compressed density. The relationship between Carr's 
compressibility index with powder flow properties was given by 
Aulthon [24]. 
Tablet evaluation 
a. Size Uniformity: Unless stated otherwise, the diameter of the 
tablet was not more than three times and not less than four-thirds of 
the thickness of the tablet [25]. The examination was carried out 
using twenty tablets. The examination was carried out on the 
diameter and thickness of each tablet. Then the average diameter 
and thickness of the tablet were calculated. 
b. Uniformity of Weights: Non-coated tablets ought to meet the 
weight uniformity requirements set as follows: weigh 20 tablets, 
calculate the average weight of each tablet. If weighed one by one, it 
should not be more than 2 tablets, each weighting deviates from the 
average weight greater than the value set by column A, and not one 
tablet deviates from the average weight more than the value 
determined by the column. B. If there weren’t enough 20 tablets, 10 
tablets could be used; none of the tablets deviated more than the 
average weight set by column A and none of the tablets deviated 
more than the average weight set by column B [20]. Deviation of the 
average weight of tablets can be seen in table 2. 
 
Table 2: Deviations in the average weight of tablets [11] 
Average weight (mg) Average weight deviation (%) 
A B 
<25 15 30 
26-150 10 20 
151-300 7.5 15 
>300 5 10 
 
c. Tablet hardness: Twenty tablets were randomly taken and their 
hardness measured using a hardness tester, then the average was 
calculated [24]. 
d. Tablet Friability: The friability testing tool for the laboratory was 
known as the Roche friabilator. This tool treats a number of tablets 
to the combined effect of scratches and shocks by using a kind of 
plastic box that rotates at a speed of 25±1 rpm. Usually, weighed 
tablets were placed inside the device, then run 100 rounds. The 
tablets were then cleaned and re-weighed. Losing weight allowed 
1.0% [25]. Tablets that were still intact were weighed and then 
calculated to lose weight and expressed in percentage using the 
following formula:  
 
Where: w1 = initial tablet weight, w2 = tablet weight after fragility 
test 
e. Destructive time test: Put one tablet in each tube from the basket 
then put a disc in each tube and run the tool, use water with a 
temperature of 37 °±2 °C as a medium unless stated using another 
liquid in each monograph. At the end of the time limit, as stated in 
the monograph, the basket was lifted, and all tablets were observed. 
All tablets ought to be completely destroyed. If 1 tablet or 2 tablets 
were not completely destroyed, repeated testing with 12 other 
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tablets: no less than 16 of the 18 tablets tested ought to be 
completely destroyed [21]. 
f. Dissolution tool 
(i)The device consists of a closed container made of glass or other 
inert transparent material, a motor, a metal rod driven by a motor 
and a paddle consisting of leaves and stems as a stirrer. Oars meet 
the specifications of the distance of 25 mm±2 mm between the 
leaves and the inside of the container retained during the test. The 
preparation was allowed to sink to the bottom of the container 
before the paddle starts to spin [21]. 
(ii). Dissolution Media: Dissolution media used 0.1 N HCl solution [26]. 
(iii). Tablet dissolution: The dissolution medium was put into 
dissolution medium 900 ml and then heated to 37 °±0.5 ° C. 
Ambroxol HCl tablets were put into a dissolution vessel then rotated 
at 50 rpm. Samples were taken as much as 5 ml at intervals of 5, 10, 
15, 20, 30, and 45 min. Every sample taken is then replaced with a 
dissolution medium as much as 5 ml. The sample taken was 
measured absorbance and determined its levels [26]. 
(iv). Determination of dissolved concentrations: Determination of 
the dissolved ambroxol HCl concentration using ultraviolet 
spectrophotometry at a maximum wavelength of around 244 nm. 
Within 45 min must dissolve not less than 75% of the active 
substance from the amount listed [26]. 
Data analysis 
Dissolution test data analysis used the perfect randomized complete 
block design (RCBD) method with 95% confidence in which blocks 
and groups were used [27, 28]. In this analysis time treatment acts 
as a block and variations were disintegrants as a group. 
RESULTS AND DISCUSSION 
Raw material preparation 
Preparation of the active substance ambroxol HCl based on 
European Pharmacopoeia literature [26]. Examination of additional 
substances such as Ludipress®, lactose, PVP K-30, and magnesium 
stearate is based on the Handbook of Pharmaceutical Excipient 
literature [29]. 
Tablet formulation 
In this study, four formula of ambroxol HCl tablets were made with 
Ludipress® and lactose additives. The test formula was presented in 
table 1. Mix ambroxol HCl with additives until it was homogeneous. 
The mass of the felt was then compressed. The weight of the 
resulting tablet was 220 mg and printed 200 pieces. 
Print mass evaluation 
The evaluation of the press mass was done before the tablet printing 
process. The print mass evaluation was useful to know how the state 
of the print mass before the tablet was pressed. When the print mass 
met the established standards, the tablet could be compressed. This 
test could be used as a supporting factor to determine the quality of 
the tablet. Evaluation of print mass includes resting angle, flow rate, 
real density, compressed density, and compressibility [30, 31]. From 
the results of the evaluation of the print mass, all formulas gave good 
results, so that the pressing process could be done by direct pressing 
method. The print mass evaluation results can be seen in table 3. 
 
Table 3: Print mass evaluation results 
Parameters F1 F2 F3 F4 
Break angle ( °) 
Flow rate (g/sec) 























 Notes: all data obtained from 3 measurements 
 
Tablet evaluation 
Tablet evaluation was carried out after the tablet printing process. 
Tablet evaluation was an evaluation conducted to find out that the 
tablets made have met the requirements. Tablet evaluation includes 
weight uniformity, size uniformity, hardness, friability, disintegration 
time, uniformity of dissolution and dissolution test. Flow and break 
angle tests were performed to determine the print mass flow capacity 
because if the print mass was easy to flow, the resulting tablet would 
have a good uniformity of weights. Literature, the nature of the flow 
was said to be good if it had a range of values of 4-10 g/s, said to be 
difficult to flow in the range of 1.6-4 g/s, and at values<1.6 g/s means it 
was very difficult to flow. A good resting angle value is in the range of 
25 °-30 ° and a range of 30 °-40 ° was included in a fairly good group 
[24]. On the other hand, the compressibility test was done by 
calculating the value of real tangibility and incompressible density 
through testing with a tap density device. The range of good 
compressibility was around 12-18 and in the range, 23-35 was poor 
[21]. The results obtained indicated that each formula had a poor 
compressibility value. Based on these results, it can be concluded that 
the print mass was quite good. 
It was found that Formula 1 did not meet the requirements for 
uniformity of levels listed on the Indonesian Pharmacopeia, with a 
value of 89.8735%. This could be due to the lack of homogeneity of 
ambroxol HCl during the mixing process. While the other three 
formulas met the requirements of Indonesian Pharmacopoeia 
uniformity levels because they fell within the range of requirements, 
namely 90%-110%. The results of the evaluation of ambroxol HCl 
tablets can be seen in table 4 and fig. 1. 
 
Table 4: Tablet evaluation results 
Parameters F1 F2 F3 F4 
Diameter (mm) 8.5245±0.3828 8.5235±0.3846 8.4786±0.4472 8.6349±0.13112+ 
Thickness (mm) 3.19±0.2100 3.22±0.2100 3.19±0.2150 3.22±0.2100 
Weight (mg) 220.72±0.80133 221.43±2,4265 222.22±2.0800 221.39±3,4013 
Hardness (N) 60.54±0,22270 58.35±1.5979 65.52±0.7343 48.25±0,1233 
Friability (%) 0.065±0.002 0.040±0.002 0.007±0.010 0.255±0.117 
Destruction time (min) 8.05±0.01 9.11±0.03 9.34±0.04 9.47±0.200 
Content (%) 89.8723±0.0083% 94.2778±0.00911% 108.6666±0.1011% 94.6823±0.1944% 
 Notes: all data obtained from 3 measurements 
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Fig. 1: Results of the dissolution profile of ambroxol HCl tablets 
 
Hardness testing of tablets was done by using a hardness tester. The 
results of testing the hardness of tablets from each formula were 
60.50±9.2800, 57.95±12.7298, 65.36±9.43743, and 48.175±5.5042 
this value was compromised to an official standard [32].  
Friability Test: The friability test was carried out by weighing as 
many as 10 tablets. The results of the friability testing of the four 
formulas showed good value or qualify because it was less than one 
percent, that was, 0.065, 0.038, 0.007, and 0.310. Good Friability 
indicated the tablet could withstand minor scratches or damage 
during storage [27]. 
Dissolution profile results from four ambroxol tablet formulas, only 
formula 3 (F3) fulfilled dissolution requirements according to 
European Pharmacopoeia, namely within 45 min, Q value of 
80.09946%. Formula three has high levels of ambroxol HCl based on 
assay uniformity test with a value of 108.6641%. This would have an 
impact on the active substances that would dissolve when dissolved. 
For formula 1 (F1) which had a Q value of 58.77974%, it did not 
meet the existing requirements, because, at the time of uniformity 
testing, the concentration of the active substance ambroxol HCl was 
only 89.8735%, so it affected the dissolution test. For formula 2 and 
formula 4 also did not meet the dissolution test requirements, 
according to European Pharmacopoeia. 
Data analysis 
Dissolution test data analysis used the perfect randomized 
complete block design (RCBD) with α = 0.05 where blocks and 
groups were used. In this analysis, time treatment acts as a block 
and variations in composition as a group. As a result, Ho was 
rejected, which means there was a difference in the percentage of 
dissolved HCl ambroxol between formulas using 74% Ludipress® 
without lactose addition (F1), 69% Ludipress® with 5% lactose 
(F2), 64% Ludipress® with 10% lactose (F3), 59% Ludipress® 
with 15% lactose (F4) (see table 5). 
 
Table 5: ANOVA of ambroxol HCl tablet dissolution 
Variance source dk JK KT Fcount Ftable 
Average 1 59497.082 59497.082   
Time 6 15409.826 2568.034   
Concentration 3 354.162 118.054 8.189* 4.76 
Errors 18 259.481 14.416   




In the dissolution profile of ambroxol HCl tablets with variations of 
Ludipress® and lactose additives that met the requirements of 
European Pharmacopeia was a formula with 69% Ludipress® 
additives and 10% lactose with a Q value of 80.09946% within 45 
min of testing. The other three formulas did not meet European 
Pharmacopoeia requirements with a Q value of less than 75% for 45 
min of testing. It concluded that the formulation of ambroxol HCl 
tablets with 69% Ludipress® additives and 10% lactose using a 
direct pressing method meets the requirements listed in 
Pharmacopoeia Indonesia or in Pharmacopoeia Europe. 
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